The company manages and licenses a large portfolio of iPSC-related patents—covering reprogramming, differentiation, organoids, immune cells, diagnostics, and therapeutic concepts—which licensees use in discovery, preclinical, and clinical programs; clinical results belong to licensee companies and institutions, not to iPS Academia Japan itself.
Therapeutic areas
NephrologyOncologyPulmonologyNeurology
Modalities
Induced pluripotent stem cell derived therapyCell therapyStem cell therapyBiologicDevice (diagnostic/analysis and research-use devices in portfolio)RNA therapy (mRNA switch, RNA-based tools)Small molecule (e.g., small-molecule inhibitors like guanabenz in PSP invention)
Industry
Academic Hospital/University/Research
02
Partnerships
Kyoto University (founding affiliate and main licensor of core iPSC patents)Numerous licensee companies across pharma, biotech, reagents, chemicals, foods, cosmetics, CROs, medical devices, and research instruments; by 2019, more than 200 licensees worldwide (Japan, North America, Europe, Asia).
Beyond the preview
Go deeper on iPS Academia Japan.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
Trial phase
Status
Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
Partners
Deal terms
Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
Funding rounds
Investors
Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
Peer companies
Targets
Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
Platforms
Patents
Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
Company news
Sources
Analysis
Bring the full picture into focus.
See how Gosset can support your research on iPS Academia Japan.